Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and ...

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize ...

It's a critical time to spotlight the dire health disparities affecting Black Americans, from premature deaths to maternal ...

FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

There was no association observed between lower income and increased fibrosis among New York City residents with metabolic dysfunction-associated steatohepatitis (MASH).

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...